Loading...
Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma
In the absence of a driver mutation, chemotherapy is the standard treatment option as first- and second-line therapy for advanced non-small-cell lung cancer (NSCLC). Though a large number of patients are suitable for post second-line therapies, the quality and quantity of the available drugs in this...
Na minha lista:
| Udgivet i: | Onco Targets Ther |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5261838/ https://ncbi.nlm.nih.gov/pubmed/28176910 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S126613 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|